Present Developments in the Creation of Sophisticated Acinetobacter Therapies

Acinetobacter baumannii is a common global source of infections linked to healthcare that have a high morbidity and fatality rate. Due to the fast emergence of multidrug-resistant and very drugresistant strains of A. baumannii, the therapeutic management of these infections has become much more challenging. Therefore, the creation of innovative intervention techniques is desperately needed to counteract this infection, which is resistant to several drugs. One of the best medical treatments for infection management is vaccination, which also has the potential to prevent A. baumannii from developing multidrug resistance. Here, we focused on the three most crucial preclinical vaccine development steps: immunological correlates of protection, antigen selection, and model organisms for effectiveness assessment. We also highlighted current developments and future obstacles in the production of A. baumannii vaccines.